Top

International Journal of Pediatric Endocrinology

Published in:

Open Access 01-12-2016 | Case report

Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease

Authors: Vidya Puthenpura, Kinjal Desai, Andrew Bauer, Ian Marshall

Published in: International Journal of Pediatric Endocrinology | Issue 1/2016

Abstract

Background

Agranulocytosis is regarded as a rare side effect of methimazole (MMI) therapy that occurs in a dose dependent manner and that usually develops within the first 3–6 months of treatment. Although delayed development beyond this timeline has been documented in adults, very few children have been reported with this presentation.

Case presentation

We present a 6-year old patient who developed agranulocytosis 18 months after the start of MMI therapy.

Conclusions

This is an unusual case of a 6-year old patient who developed this serious side effect on stable MMI therapy well beyond the typical timeline. Our review of the literature revealed that there really is inconclusive data on the incidence, time, and dose-dependency of MMI-induced agranulocytosis in the pediatric Graves’ disease population.

Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab. 2007;92(3):801–3.CrossRefPubMed

Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–17.CrossRefPubMed

Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves’ disease treated using antithyroid medication. Thyroid. 2007;17(11):1103–7.CrossRefPubMed

Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves’ disease in children. Int J Pediatr Endocrinol. 2010; Epub.

Rivkees SA. 63 years and 715 days to the “boxed warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol. 2010; Epub.

Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360(15):1574–5.CrossRefPubMed

Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol. 2009; Epub.

Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–23.CrossRefPubMed

Minamitani K, Oikawa J, Wataki K, Kashima K, Hoshi M, et al. A report of three girls with antithyroid drug-induced agranulocytosis; retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin Pediatr Endocrinol. 2011;20(2):39–46.CrossRefPubMedPubMedCentral

10.

Salama A, Schutz B, Kiefel V, Breithaupt H, Mueller-Eckhardt CM. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol. 1989;72(2):127–32.CrossRefPubMed

11.

Yang J, Xiao XH, Zhou LZ, Chen YJ, Liu JH, Cao RX, Wen GB. The relationship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis. Endocr J. 2013;60(2):185–9.CrossRefPubMed

12.

Rivkees SA. Pediatric Graves’ disease: management in the post-propylthiouracil Era. Int J Pediatr Endocrinol. 2014; Epub.

13.

Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19(6):559–63.CrossRefPubMed

14.

Sheng WH, Hung CC, Chen YC, Fang CT, Hsieh SM, et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. Q J Med. 1999;92(8):455–61.CrossRef

15.

Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab. 1993;77(5):1356–60.PubMed

16.

Fukata S, Kanji K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid. 1999;9(1):29–31.CrossRefPubMed

17.

Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83(11):3767–76.PubMed

18.

Read Jr CH, Tansey MJ, Menda Y. A thirty-six year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89(9):4229–33.CrossRefPubMed

19.

Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab. 2007;92(3):797–800.CrossRefPubMed

Title: Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease
Authors: Vidya Puthenpura
Kinjal Desai
Andrew Bauer
Ian Marshall
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: International Journal of Pediatric Endocrinology / Issue 1/2016
Electronic ISSN: 1687-9856
DOI: https://doi.org/10.1186/s13633-016-0034-6

ACC 2024 Congress

Springer Medicine

Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease

Abstract

Background

Case presentation

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Growth and descent of the testes in infants with hypogonadotropic hypogonadism receiving subcutaneous gonadotropin infusion

Pediatric thyroid surgery and management of thyroid nodules – an institutional experience over a 10-year period

Do 6-8 year old girls with central precocious puberty need routine brain imaging?

46,XY disorder of sex development due to 17-beta hydroxysteroid dehydrogenase type 3 deficiency: a plea for timely genetic testing

Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues

Rabson Mendenhall Syndrome caused by a novel missense mutation